erlotinib hydrochloride has been researched along with palladium in 1 studies
| Studies (erlotinib hydrochloride) | Trials (erlotinib hydrochloride) | Recent Studies (post-2010) (erlotinib hydrochloride) | Studies (palladium) | Trials (palladium) | Recent Studies (post-2010) (palladium) |
|---|---|---|---|---|---|
| 4,353 | 786 | 3,033 | 12,528 | 97 | 6,637 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Agnihotri, VK; Ansari, AJ; Joshi, G; Kalra, S; Kumar, R; Maurya, AK; Sawant, DM; Singh, S; Yadav, UP | 1 |
1 other study(ies) available for erlotinib hydrochloride and palladium
| Article | Year |
|---|---|
Exploration of Pd-catalysed four-component tandem reaction for one-pot assembly of pyrazolo[1,5-c]quinazolines as potential EGFR inhibitors.
Topics: Apoptosis; Binding Sites; Catalysis; Catalytic Domain; Cell Line, Tumor; Drug Design; Drug Screening Assays, Antitumor; ErbB Receptors; Erlotinib Hydrochloride; G1 Phase Cell Cycle Checkpoints; Humans; Membrane Potential, Mitochondrial; Molecular Docking Simulation; Palladium; Protein Kinase Inhibitors; Pyrazoles; Quinazolines; Reactive Oxygen Species; Structure-Activity Relationship | 2019 |